Merck (MRK) Equity Average (2009 - 2026)

Merck has disclosed Equity Average across 18 years of filings, most recently posting $49.3 billion for Q1 2026.

• In Q1 2026, Equity Average rose 3.98% year-over-year to $49.3 billion; the TTM figure through Mar 2026 stood at $49.3 billion (up 3.98% YoY), while the FY2025 annual figure was $49.5 billion, up 17.89% from the prior year.
• Equity Average slipped to $49.3 billion in Q1 2026, from $52.3 billion in the prior quarter.
• Over the last five years, Equity Average for MRK reached as high as $52.3 billion in Q4 2025 and fell as low as $39.0 billion in Q1 2024.
• The 5-year median for Equity Average is $44.1 billion (2024), against an average of $44.6 billion.
• Annual changes were most pronounced in 2022 — Equity Average jumped 51.04% — and 2024, when it fell 16.03%.
• A 5-year view of Equity Average shows it stood at $45.3 billion in 2022, then fell by 12.86% to $39.5 billion in 2023, then advanced by 15.2% to $45.5 billion in 2024, then advanced by 14.93% to $52.3 billion in 2025, then declined by 5.71% to $49.3 billion in 2026.
• According to Business Quant data, Equity Average over the past three periods registered $49.3 billion, $52.3 billion, and $50.5 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.